BTG3 and prostate carcinoma: This is in agreement with our previous observation and with observations from others that BTG3 is downregulated in prostate cancers.13, 14 Within the BTG3-downregulated tumors (≦Normal; Figure 7h), it was observed that phospho-AKT (pT308) staining was increased as the disease progresses from differentiated or poorly differentiated (grades 1–3) to undifferentiated (grade 4) stage (P=0.02; Figure 7h).